Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis [PublishAheadOfPrint]

Background

Patients with severe coccidioidomycosis infections are often treated with either amphotericin-B lipid complex (ABLC) or liposomal amphotericin-B (L-AmB). Outcomes data with these agents in severe coccidioidomycosis are currently lacking. The purpose of this study is to evaluate the efficacy and toxicity of ABLC and L-AmB in treating severe coccidioidomycosis.

Methods

A retrospective, pre-post study design was employed. Chart reviews were completed from 01/01/2005 to 12/31/2014 for all patients who received lipid-based amphotericin B. Inclusion criteria having a follow up complement fixation (CF) titer or a treatment emergent adverse event (TEAE) prior to follow up. Those with meningeal involvement and pregnant patients were excluded. Treatment outcomes were assessed based on documented completion of therapy as well symptoms, complement fixation (CF) titer, and changes to laboratory monitoring parameters.

Results

A total of 108 patients were identified, 69 of which met the inclusion criteria. There were no statistical differences in demographics or disease burden in those that received ABLC and those that received L-AmB, except those who received L-AmB were more likely to have previously diagnosed chronic kidney disease (nL-AmB=4, 12.5% vs nABLC=0, 0.0%; p=0.042) and have a lower creatinine clearance at the start of therapy (L-AmB=79.6 mg/dL vs ABLC=100.4mg/dL; p=0.008). Successful treatment was achieved in 27 (73.0%) of ABLC patients and 22 (68.8%) of L-AmB patients (p=0.700). Amphotericin B was discontinued due to documented completion of therapy for 17 (45.9%) ABLC patients and 18 (56.3%) L-AmB patients (p=0.553). Acute kidney injury (AKI) was the documented reason of treatment cessation for 10 (27.0%) ABLC and 1 (3.1%) L-AmB patient (p=0.007).

Conclusion

ABLC and L-AmB both appear to be equally efficacious in the treatment of severe coccidioidomycosis. L-AmB may have less renal toxicity than ABLC and may be the preferred 88 agent in baseline renal impairment.

https://ift.tt/2Jmo1w6